⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2024Journal of Health Care for the Poor and Underserved

A Real-world Study Evaluating the Clinical Factors Associated with the Initial SGLT2 Inhibitor Prescription

Michelle Chu Mimi Lou Mengxi Wang Allison Flores

View at Publisher

Ask AI

Bookmark

Share

Abstract

The American Diabetes Association (ADA) guidelines prioritize Sodicum-glucose transporter-2-inhibitors (SGLT2i) given cardio-renal and glycemic benefits. This study was conducted to observe clinical factors associated with initial SGLT2i prescription in type 2 diabetes patients eligible for SGLT2i by the ADA.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chu et al. (2024) studied this question.

synapsesocial.com/papers/68e5e1d3b6db643587576225 https://doi.org/10.1353/hpu.2024.a934303

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Impact of American Diabetes Association 2022 Guidelines on Prescribing Rates of Sodium-Glucose Cotransporter-2 Inhibitors in Ambulatory Care Organization Patients With Type 2 Diabetes2024 · 1 citations
2Prescribing Patterns for Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Chronic Kidney Disease: Retrospective Analysis at an Academic Family Medicine CenterClinical Guideline · 2026
3Impact of SGLT2 Inhibitors on Multiple Cardiometabolic Risk Factors: A Retrospective Cohort Studycohort · 2026 · 1 citations
4Real-Time Use of SGLT2i Verified in Pre-dialysis: The RSVP Cross-sectional Study2024 · 2 citations
5Clinical efficacy, safety, and predictors of treatment response to SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a retrospective comparative studyCohort Study · 2026

More related papers

31-PUB: Efficacy and Safety of Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i) vs. Dipeptidyl Peptidase 4 Inhibitor (DPP4i) as Initiator Therapy with Type 2 Diabetes on Cardiovascular Outcomes—A Systematic Review and Meta-analysis2024
SGLT2 Inhibitor and GLP‐1 Receptor Agonist Prescriptions in Newly Diagnosed Type 2 Diabetes Patients With Cardiorenal Risks: A Cross‐Sectional Study2025
Real-Life Prescribing of SGLT2 Inhibitors: How to Handle the Other Medications, Including Glucose-Lowering Drugs and Diuretics2021

More from Journal of Health Care for the Poor and Underserved

Associations Between Socioeconomic Disadvantage and Rurality With New Diagnoses of Atrial FibrillationSat,
Characteristics of Adults Participating in Community Blood Pressure Screening Events: An Exploratory Cross-Sectional AnalysisSat,